CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

@article{Tefferi2014CALRVJ,
  title={CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons},
  author={A. Tefferi and T. Lasho and C. Finke and R. Knudson and R. Ketterling and C. Hanson and M. Maffioli and D. Caramazza and F. Passamonti and A. Pardanani},
  journal={Leukemia},
  year={2014},
  volume={28},
  pages={1472-1477}
}
Calreticulin (CALR) mutations were recently described in JAK2 and MPL unmutated primary myelofibrosis (PMF) and essential thrombocythemia. In the current study, we compared the clinical, cytogenetic and molecular features of patients with PMF with or without CALR, JAK2 or MPL mutations. Among 254 study patients, 147 (58%) harbored JAK2, 63 (25%) CALR and 21 (8.3%) MPL mutations; 22 (8.7%) patients were negative for all three mutations, whereas one patient expressed both JAK2 and CALR mutations… Expand
390 Citations

Paper Mentions

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
  • 14
  • Highly Influenced
  • PDF
Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis
  • 18
Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia
  • 7
CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.
  • 16
  • Highly Influenced
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Mutations and prognosis in primary myelofibrosis
  • 510
  • PDF
Somatic mutations of calreticulin in myeloproliferative neoplasms.
  • 1,376
  • PDF
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
  • 1,290
  • PDF
...
1
2
3
4
...